Over the past decade, the therapeutic strategy of inflammatory bowel diseases (IBD) has evolved owing to treatments’ ability to heal lesions. IBD therapy currently aims at treating more than just symptoms in order to achieve a deep remission. Early initiation of effective drugs, such as immunosuppressive agents and biologics, further prevents irreversible damages. This strategy of treating until reaching this predefined objective impacts the disease course by reducing complications, hospitalizations, and the need for surgery. Strict monitoring using objective parameters is essential to assess treatment adequacy and make the necessary adjustments to achieve this deep remission.